Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Merchants Bancorp Pref D | MBINM | Nov 12, 2024 | 26.44 | -0.38 |
Merck & Co | MRK | Nov 12, 2024 | 98.58 | -2.13 |
Mercurity Fintech | MFH | Nov 12, 2024 | 3.38 | +44.44 |
Mercury General | MCY | Nov 12, 2024 | 73.92 | -1.68 |
Mercury Systems | MRCY | Nov 12, 2024 | 43.64 | -0.61 |
Mereo BioPharma ADR | MREO | Nov 12, 2024 | 4.10 | -4.21 |
Meridian | MRBK | Nov 12, 2024 | 13.85 | 0.00 |
MeridianLink | MLNK | Nov 12, 2024 | 24.37 | -1.02 |
Merit Medical Systems | MMSI | Nov 12, 2024 | 104.24 | +0.13 |
Meritage Homes | MTH | Nov 12, 2024 | 180.85 | -4.82 |
Merrill Lynch & Co. | IPB | Nov 12, 2024 | 25.85 | 0.00 |
Mersana Therapeutics | MRSN | Nov 12, 2024 | 2.20 | -13.04 |
Merus N.V | MRUS | Nov 12, 2024 | 51.63 | -2.51 |
Mesa Air Group | MESA | Nov 12, 2024 | 0.94 | -0.05 |
Mesa Laboratories | MLAB | Nov 12, 2024 | 112.40 | -5.50 |
Mesa Royalty Trust | MTR | Nov 12, 2024 | 5.95 | -1.82 |
Mesabi Royalty Trust | MSB | Nov 12, 2024 | 25.65 | -0.04 |
Mesoblast ADR | MESO | Nov 12, 2024 | 9.95 | +2.21 |
Meta Materials | MMAT | Nov 12, 2024 | 0.64 | 0.00 |
Meta Platforms A | META | Nov 12, 2024 | 584.82 | +0.28 |
Metagenomi | MGX | Nov 12, 2024 | 2.21 | +5.74 |
Metal Sky Star Acquisition | MSSA | Nov 12, 2024 | 11.65 | 0.00 |
Metalla Royalty & Streaming | MTA | Nov 12, 2024 | 3.14 | -2.48 |
Metallus | MTUS | Nov 12, 2024 | 15.79 | -3.84 |
Metals Acquisition | MTAL | Nov 12, 2024 | 12.70 | -2.91 |
Methalpa Technology Holding | MATH | Nov 12, 2024 | 1.23 | +1.34 |
Methanex | MEOH | Nov 12, 2024 | 42.33 | -0.17 |
Methode Electronics | MEI | Nov 12, 2024 | 9.72 | -4.71 |
MetLife | MET | Nov 12, 2024 | 82.20 | +0.53 |
Metlife Pref A | MET-A | Nov 12, 2024 | 24.46 | -0.81 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.